2020 Anesthetic Effect Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Anesthetic Effect pipeline report presents a comprehensive overview of the research and development of Anesthetic Effect drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, 9 drugs in Pre-clinical phase, three drugs in Phase 1, five drugs in Phase 3, and two drugs in pre-registration
As of February 2020, the Anesthetic Effect pipeline remains robust with 21 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Anesthetic Effect treatment. Diverse types of targeted therapies are being explored through clinical trials including GABA A receptor agonists; muscle relaxant antagonist; Nav1.7 voltage-gated sodium channel inhibitors; Neuromuscular blocking agents; Sodium channel antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Anesthetic Effect drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Anesthetic Effect pipeline drugs profiled in the report include- APC310, Flexicaine (lidocaine/tetracaine), alphaxalone, inhaled anesthetic agents, neosaxitoxin and bupivacaine, Aom0765, HYR-PB21, HR7056 (Remimazolam Tosilate), cocaine hydrochloride, mdc-CMV (ropivacaine), Lidocaine, remimazolam (ONO-2745), propofol, L-cysteine , RP-1000, RP-2000, HSK3486, KL100137, Nav1.7 voltage-gated sodium channel inhibitors, SPR819, fospropofol disodium
As of February 2020, the Anesthetic Effect pipeline remains robust with 21 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Anesthetic Effect treatment. Diverse types of targeted therapies are being explored through clinical trials including GABA A receptor agonists; muscle relaxant antagonist; Nav1.7 voltage-gated sodium channel inhibitors; Neuromuscular blocking agents; Sodium channel antagonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Anesthetic Effect drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Anesthetic Effect development
- Anesthetic Effect pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Anesthetic Effect pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Anesthetic Effect pipeline candidates included
- Business overview and snapshot of all companies involved in Anesthetic Effect pipeline are included
- Latest market and pipeline developments are provided in the report
Anesthetic Effect pipeline drugs profiled in the report include- APC310, Flexicaine (lidocaine/tetracaine), alphaxalone, inhaled anesthetic agents, neosaxitoxin and bupivacaine, Aom0765, HYR-PB21, HR7056 (Remimazolam Tosilate), cocaine hydrochloride, mdc-CMV (ropivacaine), Lidocaine, remimazolam (ONO-2745), propofol, L-cysteine , RP-1000, RP-2000, HSK3486, KL100137, Nav1.7 voltage-gated sodium channel inhibitors, SPR819, fospropofol disodium
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Anesthetic Effect Condition
2.3 Anesthetic Effect Pipeline Snapshot, 2020
2.4 Companies investing in Anesthetic Effect pipeline therapeutics
2.5 Phase wise Anesthetic Effect Pipeline Candidates
2.6 Most Researched Mechanism of Action of Anesthetic Effect Pipeline Products
2.7 Route of Administration of Anesthetic Effect Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Andros Pharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Baudax Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Crescita Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Drawbridge Pharmaceuticals Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Expanesthetics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.7 Hangzhou Adamerck Pharmlabs Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Hefei Cosource Pharmaceutical Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Lannett Co Inc Overview, Contacts and ASD Pipeline Drugs
3.11 MedinCell SA Overview, Contacts and ASD Pipeline Drugs
3.12 NutriBand Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Paion AG Overview, Contacts and ASD Pipeline Drugs
3.14 Phosphagenics Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Recro Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.16 Sichuan Haisco Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Sichuan Kelun Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 SiteOne Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.19 Sphaera Pharma Pte Ltd Overview, Contacts and ASD Pipeline Drugs
3.20 Yichang Humanwell Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 APC310 Drug Details
4.1.1 APC310 Current Status
4.1.2 APC310 Drug Overview
4.1.3 APC310 Mechanism of Action
4.1.4 APC310 Licensing/Collaboration Companies
4.1.5 APC310 Clinical Trials
4.2 Flexicaine (lidocaine/tetracaine) Drug Details
4.2.1 Flexicaine (lidocaine/tetracaine) Current Status
4.2.2 Flexicaine (lidocaine/tetracaine) Drug Overview
4.2.3 Flexicaine (lidocaine/tetracaine) Mechanism of Action
4.2.4 Flexicaine (lidocaine/tetracaine) Licensing/Collaboration Companies
4.2.5 Flexicaine (lidocaine/tetracaine) Clinical Trials
4.3 alphaxalone Drug Details
4.3.1 alphaxalone Current Status
4.3.2 alphaxalone Drug Overview
4.3.3 alphaxalone Mechanism of Action
4.3.4 alphaxalone Licensing/Collaboration Companies
4.3.5 alphaxalone Clinical Trials
4.4 inhaled anesthetic agents Drug Details
4.4.1 inhaled anesthetic agents Current Status
4.4.2 inhaled anesthetic agents Drug Overview
4.4.3 inhaled anesthetic agents Mechanism of Action
4.4.4 inhaled anesthetic agents Licensing/Collaboration Companies
4.4.5 inhaled anesthetic agents Clinical Trials
4.5 neosaxitoxin and bupivacaine Drug Details
4.5.1 neosaxitoxin and bupivacaine Current Status
4.5.2 neosaxitoxin and bupivacaine Drug Overview
4.5.3 neosaxitoxin and bupivacaine Mechanism of Action
4.5.4 neosaxitoxin and bupivacaine Licensing/Collaboration Companies
4.5.5 neosaxitoxin and bupivacaine Clinical Trials
4.6 Aom0765 Drug Details
4.6.1 Aom0765 Current Status
4.6.2 Aom0765 Drug Overview
4.6.3 Aom0765 Mechanism of Action
4.6.4 Aom0765 Licensing/Collaboration Companies
4.6.5 Aom0765 Clinical Trials
4.7 HYR-PB21 Drug Details
4.7.1 HYR-PB21 Current Status
4.7.2 HYR-PB21 Drug Overview
4.7.3 HYR-PB21 Mechanism of Action
4.7.4 HYR-PB21 Licensing/Collaboration Companies
4.7.5 HYR-PB21 Clinical Trials
4.8 HR7056 (Remimazolam Tosilate) Drug Details
4.8.1 HR7056 (Remimazolam Tosilate) Current Status
4.8.2 HR7056 (Remimazolam Tosilate) Drug Overview
4.8.3 HR7056 (Remimazolam Tosilate) Mechanism of Action
4.8.4 HR7056 (Remimazolam Tosilate) Licensing/Collaboration Companies
4.8.5 HR7056 (Remimazolam Tosilate) Clinical Trials
4.9 cocaine hydrochloride Drug Details
4.9.1 cocaine hydrochloride Current Status
4.9.2 cocaine hydrochloride Drug Overview
4.9.3 cocaine hydrochloride Mechanism of Action
4.9.4 cocaine hydrochloride Licensing/Collaboration Companies
4.9.5 cocaine hydrochloride Clinical Trials
4.10 mdc-CMV (ropivacaine) Drug Details
4.10.1 mdc-CMV (ropivacaine) Current Status
4.10.2 mdc-CMV (ropivacaine) Drug Overview
4.10.3 mdc-CMV (ropivacaine) Mechanism of Action
4.10.4 mdc-CMV (ropivacaine) Licensing/Collaboration Companies
4.10.5 mdc-CMV (ropivacaine) Clinical Trials
4.11 Lidocaine Drug Details
4.11.1 Lidocaine Current Status
4.11.2 Lidocaine Drug Overview
4.11.3 Lidocaine Mechanism of Action
4.11.4 Lidocaine Licensing/Collaboration Companies
4.11.5 Lidocaine Clinical Trials
4.12 remimazolam (ONO-2745) Drug Details
4.12.1 remimazolam (ONO-2745) Current Status
4.12.2 remimazolam (ONO-2745) Drug Overview
4.12.3 remimazolam (ONO-2745) Mechanism of Action
4.12.4 remimazolam (ONO-2745) Licensing/Collaboration Companies
4.12.5 remimazolam (ONO-2745) Clinical Trials
4.13 propofol Drug Details
4.13.1 propofol Current Status
4.13.2 propofol Drug Overview
4.13.3 propofol Mechanism of Action
4.13.4 propofol Licensing/Collaboration Companies
4.13.5 propofol Clinical Trials
4.14 L-cysteine Drug Details
4.14.1 L-cysteine Current Status
4.14.2 L-cysteine Drug Overview
4.14.3 L-cysteine Mechanism of Action
4.14.4 L-cysteine Licensing/Collaboration Companies
4.14.5 L-cysteine Clinical Trials
4.15 RP-1000 Drug Details
4.15.1 RP-1000 Current Status
4.15.2 RP-1000 Drug Overview
4.15.3 RP-1000 Mechanism of Action
4.15.4 RP-1000 Licensing/Collaboration Companies
4.15.5 RP-1000 Clinical Trials
4.16 RP-2000 Drug Details
4.16.1 RP-2000 Current Status
4.16.2 RP-2000 Drug Overview
4.16.3 RP-2000 Mechanism of Action
4.16.4 RP-2000 Licensing/Collaboration Companies
4.16.5 RP-2000 Clinical Trials
4.17 HSK3486 Drug Details
4.17.1 HSK3486 Current Status
4.17.2 HSK3486 Drug Overview
4.17.3 HSK3486 Mechanism of Action
4.17.4 HSK3486 Licensing/Collaboration Companies
4.17.5 HSK3486 Clinical Trials
4.18 KL100137 Drug Details
4.18.1 KL100137 Current Status
4.18.2 KL100137 Drug Overview
4.18.3 KL100137 Mechanism of Action
4.18.4 KL100137 Licensing/Collaboration Companies
4.18.5 KL100137 Clinical Trials
4.19 Nav1.7 voltage-gated sodium channel inhibitors Drug Details
4.19.1 Nav1.7 voltage-gated sodium channel inhibitors Current Status
4.19.2 Nav1.7 voltage-gated sodium channel inhibitors Drug Overview
4.19.3 Nav1.7 voltage-gated sodium channel inhibitors Mechanism of Action
4.19.4 Nav1.7 voltage-gated sodium channel inhibitors Licensing/Collaboration Companies
4.19.5 Nav1.7 voltage-gated sodium channel inhibitors Clinical Trials
4.20 SPR819 Drug Details
4.20.1 SPR819 Current Status
4.20.2 SPR819 Drug Overview
4.20.3 SPR819 Mechanism of Action
4.20.4 SPR819 Licensing/Collaboration Companies
4.20.5 SPR819 Clinical Trials
4.21 fospropofol disodium Drug Details
4.21.1 fospropofol disodium Current Status
4.21.2 fospropofol disodium Drug Overview
4.21.3 fospropofol disodium Mechanism of Action
4.21.4 fospropofol disodium Licensing/Collaboration Companies
4.21.5 fospropofol disodium Clinical Trials
5. LATEST ANESTHETIC EFFECT PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Anesthetic Effect Condition
2.3 Anesthetic Effect Pipeline Snapshot, 2020
2.4 Companies investing in Anesthetic Effect pipeline therapeutics
2.5 Phase wise Anesthetic Effect Pipeline Candidates
2.6 Most Researched Mechanism of Action of Anesthetic Effect Pipeline Products
2.7 Route of Administration of Anesthetic Effect Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Andros Pharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Baudax Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Crescita Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Drawbridge Pharmaceuticals Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Expanesthetics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.7 Hangzhou Adamerck Pharmlabs Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Hefei Cosource Pharmaceutical Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Lannett Co Inc Overview, Contacts and ASD Pipeline Drugs
3.11 MedinCell SA Overview, Contacts and ASD Pipeline Drugs
3.12 NutriBand Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Paion AG Overview, Contacts and ASD Pipeline Drugs
3.14 Phosphagenics Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Recro Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.16 Sichuan Haisco Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Sichuan Kelun Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 SiteOne Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.19 Sphaera Pharma Pte Ltd Overview, Contacts and ASD Pipeline Drugs
3.20 Yichang Humanwell Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 APC310 Drug Details
4.1.1 APC310 Current Status
4.1.2 APC310 Drug Overview
4.1.3 APC310 Mechanism of Action
4.1.4 APC310 Licensing/Collaboration Companies
4.1.5 APC310 Clinical Trials
4.2 Flexicaine (lidocaine/tetracaine) Drug Details
4.2.1 Flexicaine (lidocaine/tetracaine) Current Status
4.2.2 Flexicaine (lidocaine/tetracaine) Drug Overview
4.2.3 Flexicaine (lidocaine/tetracaine) Mechanism of Action
4.2.4 Flexicaine (lidocaine/tetracaine) Licensing/Collaboration Companies
4.2.5 Flexicaine (lidocaine/tetracaine) Clinical Trials
4.3 alphaxalone Drug Details
4.3.1 alphaxalone Current Status
4.3.2 alphaxalone Drug Overview
4.3.3 alphaxalone Mechanism of Action
4.3.4 alphaxalone Licensing/Collaboration Companies
4.3.5 alphaxalone Clinical Trials
4.4 inhaled anesthetic agents Drug Details
4.4.1 inhaled anesthetic agents Current Status
4.4.2 inhaled anesthetic agents Drug Overview
4.4.3 inhaled anesthetic agents Mechanism of Action
4.4.4 inhaled anesthetic agents Licensing/Collaboration Companies
4.4.5 inhaled anesthetic agents Clinical Trials
4.5 neosaxitoxin and bupivacaine Drug Details
4.5.1 neosaxitoxin and bupivacaine Current Status
4.5.2 neosaxitoxin and bupivacaine Drug Overview
4.5.3 neosaxitoxin and bupivacaine Mechanism of Action
4.5.4 neosaxitoxin and bupivacaine Licensing/Collaboration Companies
4.5.5 neosaxitoxin and bupivacaine Clinical Trials
4.6 Aom0765 Drug Details
4.6.1 Aom0765 Current Status
4.6.2 Aom0765 Drug Overview
4.6.3 Aom0765 Mechanism of Action
4.6.4 Aom0765 Licensing/Collaboration Companies
4.6.5 Aom0765 Clinical Trials
4.7 HYR-PB21 Drug Details
4.7.1 HYR-PB21 Current Status
4.7.2 HYR-PB21 Drug Overview
4.7.3 HYR-PB21 Mechanism of Action
4.7.4 HYR-PB21 Licensing/Collaboration Companies
4.7.5 HYR-PB21 Clinical Trials
4.8 HR7056 (Remimazolam Tosilate) Drug Details
4.8.1 HR7056 (Remimazolam Tosilate) Current Status
4.8.2 HR7056 (Remimazolam Tosilate) Drug Overview
4.8.3 HR7056 (Remimazolam Tosilate) Mechanism of Action
4.8.4 HR7056 (Remimazolam Tosilate) Licensing/Collaboration Companies
4.8.5 HR7056 (Remimazolam Tosilate) Clinical Trials
4.9 cocaine hydrochloride Drug Details
4.9.1 cocaine hydrochloride Current Status
4.9.2 cocaine hydrochloride Drug Overview
4.9.3 cocaine hydrochloride Mechanism of Action
4.9.4 cocaine hydrochloride Licensing/Collaboration Companies
4.9.5 cocaine hydrochloride Clinical Trials
4.10 mdc-CMV (ropivacaine) Drug Details
4.10.1 mdc-CMV (ropivacaine) Current Status
4.10.2 mdc-CMV (ropivacaine) Drug Overview
4.10.3 mdc-CMV (ropivacaine) Mechanism of Action
4.10.4 mdc-CMV (ropivacaine) Licensing/Collaboration Companies
4.10.5 mdc-CMV (ropivacaine) Clinical Trials
4.11 Lidocaine Drug Details
4.11.1 Lidocaine Current Status
4.11.2 Lidocaine Drug Overview
4.11.3 Lidocaine Mechanism of Action
4.11.4 Lidocaine Licensing/Collaboration Companies
4.11.5 Lidocaine Clinical Trials
4.12 remimazolam (ONO-2745) Drug Details
4.12.1 remimazolam (ONO-2745) Current Status
4.12.2 remimazolam (ONO-2745) Drug Overview
4.12.3 remimazolam (ONO-2745) Mechanism of Action
4.12.4 remimazolam (ONO-2745) Licensing/Collaboration Companies
4.12.5 remimazolam (ONO-2745) Clinical Trials
4.13 propofol Drug Details
4.13.1 propofol Current Status
4.13.2 propofol Drug Overview
4.13.3 propofol Mechanism of Action
4.13.4 propofol Licensing/Collaboration Companies
4.13.5 propofol Clinical Trials
4.14 L-cysteine Drug Details
4.14.1 L-cysteine Current Status
4.14.2 L-cysteine Drug Overview
4.14.3 L-cysteine Mechanism of Action
4.14.4 L-cysteine Licensing/Collaboration Companies
4.14.5 L-cysteine Clinical Trials
4.15 RP-1000 Drug Details
4.15.1 RP-1000 Current Status
4.15.2 RP-1000 Drug Overview
4.15.3 RP-1000 Mechanism of Action
4.15.4 RP-1000 Licensing/Collaboration Companies
4.15.5 RP-1000 Clinical Trials
4.16 RP-2000 Drug Details
4.16.1 RP-2000 Current Status
4.16.2 RP-2000 Drug Overview
4.16.3 RP-2000 Mechanism of Action
4.16.4 RP-2000 Licensing/Collaboration Companies
4.16.5 RP-2000 Clinical Trials
4.17 HSK3486 Drug Details
4.17.1 HSK3486 Current Status
4.17.2 HSK3486 Drug Overview
4.17.3 HSK3486 Mechanism of Action
4.17.4 HSK3486 Licensing/Collaboration Companies
4.17.5 HSK3486 Clinical Trials
4.18 KL100137 Drug Details
4.18.1 KL100137 Current Status
4.18.2 KL100137 Drug Overview
4.18.3 KL100137 Mechanism of Action
4.18.4 KL100137 Licensing/Collaboration Companies
4.18.5 KL100137 Clinical Trials
4.19 Nav1.7 voltage-gated sodium channel inhibitors Drug Details
4.19.1 Nav1.7 voltage-gated sodium channel inhibitors Current Status
4.19.2 Nav1.7 voltage-gated sodium channel inhibitors Drug Overview
4.19.3 Nav1.7 voltage-gated sodium channel inhibitors Mechanism of Action
4.19.4 Nav1.7 voltage-gated sodium channel inhibitors Licensing/Collaboration Companies
4.19.5 Nav1.7 voltage-gated sodium channel inhibitors Clinical Trials
4.20 SPR819 Drug Details
4.20.1 SPR819 Current Status
4.20.2 SPR819 Drug Overview
4.20.3 SPR819 Mechanism of Action
4.20.4 SPR819 Licensing/Collaboration Companies
4.20.5 SPR819 Clinical Trials
4.21 fospropofol disodium Drug Details
4.21.1 fospropofol disodium Current Status
4.21.2 fospropofol disodium Drug Overview
4.21.3 fospropofol disodium Mechanism of Action
4.21.4 fospropofol disodium Licensing/Collaboration Companies
4.21.5 fospropofol disodium Clinical Trials
5. LATEST ANESTHETIC EFFECT PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
